CSTL News and Press, Castle Biosciences Inc.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...

2024-07-12 14:30:06 ET More on Exact Sciences: Exact Sciences: Still No Reason To Own Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Exact Sciences initiated at sector outperform at Scotiabank on advanced diagnostics Exact Sciences gains a...

Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...

2024-07-05 12:07:45 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosc...

Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE) 1,2 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the lat...

Maetzold selected as a winner of Ernst & Young’s prestigious annual awards among 48 visionary finalists in the Gulf South region, encompassing Central and South Texas, Louisiana and Mississippi Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innova...

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2) Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ...

2024-05-30 02:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:...